<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) carries a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>In this phase I/II study, <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> was combined with low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in 49 previously untreated patients with intermediate-2 and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status </plain></SENT>
<SENT sid="3" pm="."><plain>Mortality within the first 4 weeks was 8% </plain></SENT>
<SENT sid="4" pm="."><plain>The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments </plain></SENT>
</text></document>